Hebang Biotechnology remains bullish on glyphosate TC business

Summary: In Q1–Q3 2022, Hebang Biotechnology achieved a YoY revenue growth, while during Q3 both its revenue and net profit declined YoY, due to the unstable production and sluggish demand. For glyphosate TC business, the company remains bullis...

Glyphosate China Monthly Report 202211